高级检索
当前位置: 首页 > 详情页

Down-regulation of PTEN by HCV core protein through activating nuclear factor-kappa B

| 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Kunming 650032, Yunnan, Peoples R China [2]Kunming Gen Hosp, Dept Pathol, Kunming 650032, Yunnan, Peoples R China
出处:
ISSN:

关键词: Core protein hepatocellular carcinoma hepatitis C virus PTEN

摘要:
The hepatitis C virus (HCV) core protein is an important causative agent in HCV related hepatocellular carcinoma (HCC). Tumor suppressor gene PTEN appears to act in the liver at the crossroad of processes controlling cell proliferation. In this study we investigated the effect of the HCV core protein on the PTEN pathway in hepatocarcinogenesis. The HCV core was transfected stably into HepG2 cell. The effect of HCV core on cell proliferation and viability were detected by 3-(4, 5)-dimethylthiahiazo-(-z-y1)-3, 5-di-phenytetrazoliumromide (MTT) assay, clonogenic survival assay and Fluorescence Activating Cell Sorter (FACS) analysis. The expressions of PTEN were detected by real time RT-PCR and/or Western blot analysis, also the mechanism of down-regulation of PTEN was explored by western blot, luciferase assay and RNA interference. We found the HCV core promoted cell proliferation, survival and G2/M phase accumulation. It downregulated PTEN at mRNA and protein level and activated PTEN downstream gene Akt accompanied with NF-kappa B activation. Furthermore, the inhibition of HCV core by its specific shRNAs decreased the effect of growth promotion and G2/M phase arrest, inhibited the expression of nuclear p65 and increased PTEN expression. The activity of PTEN was restored when treated with NF-kappa B inhibitor PDTC. By luciferase assay we found that NF-kappa B inhibited PTEN promoter transcription activity directly in HCV core cells, while PDTC was contrary. Our study suggests that HCV proteins could modulate PTEN by activating NF-kappa B. Furthermore strategies designed to restore the expression of PTEN may be promising therapies for preventing HCV dependent hepatocarcinogenesis.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
最新[2023]版:
JCR分区:
出版当年[2014]版:
Q3 PATHOLOGY Q3 ONCOLOGY
最新[2023]版:
Q4 ONCOLOGY Q4 PATHOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者机构: [1]Kunming Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Kunming 650032, Yunnan, Peoples R China
通讯作者:
通讯机构: [2]Kunming Gen Hosp, Dept Pathol, Kunming 650032, Yunnan, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53611 今日访问量:17 总访问量:1665 更新日期:2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西昌路295号(650032)